Neural Therapeutics Announces Filing and Mailing of Meeting Materials for Annual and Special Meeting to Approve Series B Transactions with CWE
Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, announces that it has filed on SEDAR+ and completed the mailing of its notice of annual and special meeting, management information circular and related meeting materials (collectively, the "Mee
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-01 8:04 AM EDT | Neural Therapeutics Inc.
Three Finalists Announced for the 2026 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Bloom Burton & Co. ("Bloom Burton") is thrilled to announce the finalists for the 2026 Bloom Burton Award. Bestowed annually and nominated by the public at large, the Bloom Burton Award honours an individual who made the greatest contribution to Canada's innovative healthcare industry in the previous year. The finalists for 2026, in alphabetical order, are: Ian Mortimer, President & Chief Executive Officer, Xenon Ph
Technology, Biotechnology, Investment Banking, Health
2026-05-01 7:30 AM EDT | Bloom Burton & Co. Inc.
BYT Holdings Ltd. Anticipates Failure-to-File Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - April 30, 2026) - BYT Holdings Ltd. (CSE: BYT) ("BYT" or the "Company") has made an unsuccessful application to the British Columbia Securities Commission ("BCSC"), the Company's principal securities regulator in Canada, to approve a temporary management cease trade order ("MCTO") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), which, if granted, would have prohibited trading in securities of the Company by its
Technology, Biotechnology, Construction / Building, Machinery
2026-04-30 5:34 PM EDT | BYT Holdings Ltd.
Dr. Christina Rahm Recognized Nationally for Building Patent-Driven Manufacturing Behind The ROOT Brands Products
Franklin, Tennessee--(Newsfile Corp. - April 30, 2026) - Dr. Christina Rahm, scientist, inventor, and Founder and Chief Science Officer of The ROOT Brands, has received a Gold Stevie® Award in the 2026 American Business Awards® for Building and Scaling Patent-Driven Manufacturing Infrastructure (M
Biotechnology, Food / Beverages, Health
2026-04-30 4:45 PM EDT | DRC Ventures
BioHarvest Sciences to Report First Quarter 2026 Financial Results on May 14, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - April 30, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its first quarter 2026 financial results before the market opening on Thursday, May 14, 2026. The Company will also host a conference call and webcast at 8:00 a.m. U.S. Eastern Time to discuss the results and provide
Biotechnology, Pharmaceuticals, Health
2026-04-30 4:05 PM EDT | BioHarvest Sciences Inc.
Restart Life Advances Holy Crap Growth Strategy with New Protein SKU Nearing Commercialization
Vancouver, British Columbia--(Newsfile Corp. - April 30, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an update on its collaboration with the University of Manitoba's Richardson Centre for Food Technology and Research (RCFTR), announcing the development of a new protein-focused SKU under its Holy Crap™ brand. This initiative extends the Company's existing research collaboration with RCFTR and
Technology, Biotechnology, Health
2026-04-30 8:00 AM EDT | Restart Life Sciences Corp.
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating the OST-HER2 approach. Participants will include strategic advisors Dr. Craig Eagle and Dr. Bob Langer, and Osteosarcoma key opinion leader Dr. Peter Anderson from Cleveland Clinic. EMA and Australia TGA (ATGA) align on 3-year overall survival a
2026-04-30 6:00 AM EDT | OS Therapies
MustGrow Announces 2025 Financial Results
Investor Webcast: Thursday, April 30th at 4:00pm ET / 1:00pm PT Register/View Here: https://us02web.zoom.us/webinar/register/3117774401744/WN_eXcymymWSnicArxMPOiZVA Please join/register at least 5 minutes prior to the call. Questions emailed to info@mustgrow.ca will be addressed during the Q&A portion of the webcast. Saskatoon, Sa
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-04-29 5:00 PM EDT | MustGrow Biologics Corp.
TempraMed Announces Continuance into Ontario
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has continued out of the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) into the provincial jurisdiction of Ontario under the
Technology, Biotechnology, Pharmaceuticals, Health
2026-04-29 4:30 PM EDT | TempraMed Technologies Ltd.
Bachem Annual General Meeting 2026
Bubendorf, Switzerland--(Newsfile Corp. - April 29, 2026) - Bachem Holding AG (SIX: BANB) (“Bachem”) announced today that its Annual General Meeting 2026 has approved all proposals of the Board of Directors. A total of 78,3% of the 74‘977‘940 eligible shares were present. The Annual General Meetin
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-04-29 12:09 PM EDT | Bachem Holding AG
BioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate "Two-Lens" Growth Strategy
British Columbia and Rehovot, Israel--(Newsfile Corp. - April 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis™ technology, today announced a s
Biotechnology, Pharmaceuticals, Health
2026-04-29 8:30 AM EDT | BioHarvest Sciences Inc.
Izotropic Africa Launches Operations in Casablanca
British Columbia and Casablanca, Morocco--(Newsfile Corp. - April 29, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces the official launch of Izotropic Africa in Casablanca, Morocco, and th
2026-04-29 8:00 AM EDT | Izotropic Corporation
GridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K Filing
Boca Raton, Florida--(Newsfile Corp. - April 28, 2026) - GridAI Technologies Corp. (NASDAQ: GRDX) (the "Company") today announced that On April 22, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with the filing of periodic financial reports requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5250(c)(1), because the Company has not yet file
2026-04-28 5:20 PM EDT | GridAI Technologies Corp.
Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - April 28, 2026) - Envoy Medical® Inc. (NASDA
Biotechnology, Healthcare and Hospitals
2026-04-28 8:30 AM EDT | Envoy Medical, Inc.
Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Launches on Walmart Canada's Digital Marketplace
Vancouver, British Columbia--(Newsfile Corp. - April 28, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap Foods"), has secured a listing on Walmart Canada's online marketplace, Walmart.ca. The Company's initial product lineup has been accepted for sale, with inventory currently in transit to Walmart's fulfillment network. Product availability
Technology, Biotechnology, Health
2026-04-28 8:00 AM EDT | Restart Life Sciences Corp.
MustGrow Receives Georgia Registration for TerraSante(TM) Biofertility Product
Saskatoon, Saskatchewan--(Newsfile Corp. - April 28, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGRO
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-04-28 7:00 AM EDT | MustGrow Biologics Corp.
InMed Pharmaceuticals Amends Preferred Investment Options
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of preferred investment options previously entered into with each of Sabby Volatility Warrant Master Fund, Ltd.
Biotechnology, Pharmaceuticals
2026-04-27 5:30 PM EDT | InMed Pharmaceuticals
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
New York, New York--(Newsfile Corp. - April 27, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world le
2026-04-27 4:01 PM EDT | OS Therapies
Bachem Secures Financing of Strategic Growth Initiatives
Bubendorf, Switzerland--(Newsfile Corp. - April 27, 2026) - Bachem Holding AG (SIX: BANB) (“Bachem”) announced today the closing of a revolving credit facility of C
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-04-27 1:03 AM EDT | Bachem Holding AG
Defence Therapeutics Announces Grant of Restricted Stock Units
Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units ("RSUs") to Mr. Sebastien Plouffe, CEO and Director of the Company, vesting immediately. Each RSU entitles the
Biotechnology, Pharmaceuticals, Health
2026-04-24 6:30 PM EDT | Defence Therapeutics Inc.